WallStSmart

Biomerica Inc (BMRA)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 726436% more annual revenue ($35.48B vs $4.88M). MDT leads profitability with a 13.0% profit margin vs -74.8%. MDT earns a higher WallStSmart Score of 56/100 (C).

BMRA

Avoid

26

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -12.51

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BMRA.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMRA2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

BMRA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.37M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-69.6%2/10

ROE of -69.6% — below average capital efficiency

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : BMRA

The strongest argument for BMRA centers on Price/Book, Debt/Equity.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : BMRA

The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

BMRA profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.73 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biomerica Inc

HEALTHCARE · MEDICAL DEVICES · USA

Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology company specializing in the development and manufacturing of cutting-edge diagnostic solutions across the medical and food sectors. With a strong focus on proprietary testing methods for managing metabolic diseases, gastrointestinal disorders, and food intolerances, Biomerica is committed to improving healthcare outcomes. The company actively engages in strategic research collaborations, positioning itself to address critical unmet medical needs and harness growth opportunities in the rapidly evolving diagnostics landscape. Leveraging technological advancements and a patient-centered approach, Biomerica is well-positioned to lead transformational changes in global healthcare diagnostics.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?